July 06, 2016 11:00 ET
OTTAWA, ONTARIO--(Marketwired - July 6, 2016) - Patented Medicine Prices Review Board
In a decision dated June 23, 2016, Canada's Federal Court dismissed a constitutional challenge brought against the Patented Medicine Prices Review Board (PMPRB), an agency created by the federal government to protect consumers from excessively priced patented medicines.
The challenge was brought in September 2015 by Alexion Pharmaceuticals Inc., which sells the patented drug Soliris. This drug is currently the subject of a legal proceeding before the PMPRB into allegations that the drug is priced excessively in Canada.
In dismissing Alexion's case, the Federal Court agreed with the Attorney General of Canada that the challenge was "bereft of any chance of success" given that the constitutionality of the PMPRB and its price regulation powers have already been affirmed on multiple occasions by Canadian court decisions.
- Decision: Canada (Attorney General) v. Alexion Pharmaceuticals Inc. (Patented Medicine Prices Review Board)
Follow us on Twitter: @PMPRB_CEPMB
Sofie McCoy-AstellManager, CommunicationsPatented Medicine Prices Review Board613-960-9728Sofie.McCoy-Astell@pmprb-cepmb.gc.caTTY (telecommunications device for the hearing impaired)613-957-4373
See all RSS Newsfeeds